Last reviewed · How we verify
Fuganlin Oral Liquid
At a glance
| Generic name | Fuganlin Oral Liquid |
|---|---|
| Also known as | No other names |
| Sponsor | Guangzhou Yipinhong Pharmaceutical CO.,LTD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection) (PHASE4)
- Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fuganlin Oral Liquid CI brief — competitive landscape report
- Fuganlin Oral Liquid updates RSS · CI watch RSS
- Guangzhou Yipinhong Pharmaceutical CO.,LTD portfolio CI